Clinical Trials
94 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
M.D. Anderson Cancer Center
Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
M.D. Anderson Cancer Center
Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
ASSET
Duke University
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
M.D. Anderson Cancer Center
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
MERECA
Mendus
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
SURF
Centre Hospitalier Universitaire de Besancon
NIVOSWITCH
AIO-Studien-gGmbH
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Boehringer Ingelheim
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
UNICANCER
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
INMUNOSUN
Spanish Oncology Genito-Urinary Group
TAURUS
AVEO Pharmaceuticals, Inc.
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
IMmotion150
Hoffmann-La Roche
FARETES
Kidney Cancer Research Bureau
A Study for Participants With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Sutent
University of Michigan
SuAx
Instituto do Cancer do Estado de São Paulo
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Eli Lilly and Company
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
Case Comprehensive Cancer Center
BERAT
Central European Society for Anticancer Drug Research
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Case Comprehensive Cancer Center
SPRUCE
AHS Cancer Control Alberta
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
Taipei Veterans General Hospital, Taiwan
A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
Jiangsu HengRui Medicine Co., Ltd.
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
Sunnybrook Health Sciences Centre
ASPEN
Duke University
SUNRISES
Associació per a la Recerca Oncologica, Spain
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute